Lorlatinib and high cholesterol in ALK+ lung cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing clinical trials.
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ALK+ non-small cell lung cancer.
- You are between the ages of 18 and 80.
- You are in good enough health to handle daily activities (ECOG score 0-2).
- You have been taking Lorlatinib for at least 20 days.
- You have not been using other anti-cancer drugs during your Lorlatinib treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding cholesterol-lowering drugs to manage high cholesterol caused by lorlatinib, a targeted therapy for advanced ALK-positive non-small cell lung cancer. It aims to help patients stay on lorlatinib safely while controlling their cholesterol levels.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.